Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study.

Tibes R, Borad MJ, Dutcus CE, Reyderman L, Feit K, Eisen A, Verbel DA, Von Hoff DD.

Br J Cancer. 2018 Jun;118(12):1580-1585. doi: 10.1038/s41416-018-0099-5. Epub 2018 Jun 5.

2.

Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.

Gidal BE, Maganti R, Laurenza A, Yang H, Verbel DA, Schuck E, Ferry J.

Epilepsy Res. 2017 Aug;134:41-48. doi: 10.1016/j.eplepsyres.2017.04.018. Epub 2017 Apr 26.

3.
4.

Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas.

Dubbelman AC, Rosing H, Nijenhuis C, Huitema AD, Mergui-Roelvink M, Gupta A, Verbel D, Thompson G, Shumaker R, Schellens JH, Beijnen JH.

Invest New Drugs. 2015 Feb;33(1):233-40. doi: 10.1007/s10637-014-0181-7. Epub 2014 Nov 8.

PMID:
25377392
5.

A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib.

Donovan MJ, Kotsianti A, Bayer-Zubek V, Verbel D, Teverovskiy M, Cordon-Cardo C, Costa J, Greco FA, Hainsworth JD, Parums DV.

Eur J Cancer. 2009 May;45(8):1518-26. doi: 10.1016/j.ejca.2009.02.004. Epub 2009 Mar 9.

PMID:
19272767
6.

Comparison of models to predict clinical failure after radical prostatectomy.

Eggener SE, Vickers AJ, Serio AM, Donovan MJ, Khan FM, Bayer-Zubek V, Verbel D, Cordon-Cardo C, Reuter VE, Bianco FJ Jr, Scardino PT.

Cancer. 2009 Jan 15;115(2):303-10. doi: 10.1002/cncr.24016.

7.

Multifeature prostate cancer diagnosis and Gleason grading of histological images.

Tabesh A, Teverovskiy M, Pang HY, Kumar VP, Verbel D, Kotsianti A, Saidi O.

IEEE Trans Med Imaging. 2007 Oct;26(10):1366-78.

PMID:
17948727
8.

Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen.

Muss HB, Bunn JY, Crocker A, Plaut K, Koh J, Heintz N, Rincon M, Weaver DL, Tam D, Beatty B, Kaufman P, Donovan M, Verbel D, Weiss L.

Breast J. 2007 Jul-Aug;13(4):337-45.

PMID:
17593037
9.

Improved prediction of prostate cancer recurrence through systems pathology.

Cordon-Cardo C, Kotsianti A, Verbel DA, Teverovskiy M, Capodieci P, Hamann S, Jeffers Y, Clayton M, Elkhettabi F, Khan FM, Sapir M, Bayer-Zubek V, Vengrenyuk Y, Fogarsi S, Saidi O, Reuter VE, Scher HI, Kattan MW, Bianco FJ, Wheeler TM, Ayala GE, Scardino PT, Donovan MJ.

J Clin Invest. 2007 Jul;117(7):1876-83.

10.

Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment.

Maluf FC, Cordon-Cardo C, Verbel DA, Satagopan JM, Boyle MG, Herr H, Bajorin DF.

Ann Oncol. 2006 Nov;17(11):1677-86. Epub 2006 Sep 19.

PMID:
16984978
11.

Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy.

Morris MJ, Akhurst T, Larson SM, Ditullio M, Chu E, Siedlecki K, Verbel D, Heller G, Kelly WK, Slovin S, Schwartz L, Scher HI.

Clin Cancer Res. 2005 May 1;11(9):3210-6.

12.

Prosthetic intervention in the era of microvascular reconstruction of the mandible--a retrospective analysis of functional outcome.

Teoh KH, Patel S, Hwang F, Huryn JM, Verbel D, Zlotolow IM.

Int J Prosthodont. 2005 Jan-Feb;18(1):42-54.

PMID:
15754892
13.

Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.

Slovin SF, Ragupathi G, Musselli C, Fernandez C, Diani M, Verbel D, Danishefsky S, Livingston P, Scher HI.

Cancer Immunol Immunother. 2005 Jul;54(7):694-702. Epub 2005 Feb 22.

PMID:
15726361
15.

Loss of the tumor suppressor PML in human cancers of multiple histologic origins.

Gurrieri C, Capodieci P, Bernardi R, Scaglioni PP, Nafa K, Rush LJ, Verbel DA, Cordon-Cardo C, Pandolfi PP.

J Natl Cancer Inst. 2004 Feb 18;96(4):269-79.

PMID:
14970276
16.

p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer.

Puig P, Capodieci P, Drobnjak M, Verbel D, Prives C, Cordon-Cardo C, Di Como CJ.

Clin Cancer Res. 2003 Nov 15;9(15):5642-51.

17.

Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.

Slovin SF, Ragupathi G, Musselli C, Olkiewicz K, Verbel D, Kuduk SD, Schwarz JB, Sames D, Danishefsky S, Livingston PO, Scher HI.

J Clin Oncol. 2003 Dec 1;21(23):4292-8.

PMID:
14645418
18.

Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.

Hamlin PA, Zelenetz AD, Kewalramani T, Qin J, Satagopan JM, Verbel D, Noy A, Portlock CS, Straus DJ, Yahalom J, Nimer SD, Moskowitz CH.

Blood. 2003 Sep 15;102(6):1989-96. Epub 2003 Apr 3.

19.

Estimating survival benefit in castrate metastatic prostate cancer: decision making in proceeding to a definitive phase III trial.

Verbel DA, Kelly WK, Smaletz O, Regan K, Curley T, Heller G, Scher HI.

Urology. 2003 Jan;61(1):142-4.

PMID:
12559285
20.

Loss of p63 expression is associated with tumor progression in bladder cancer.

Urist MJ, Di Como CJ, Lu ML, Charytonowicz E, Verbel D, Crum CP, Ince TA, McKeon FD, Cordon-Cardo C.

Am J Pathol. 2002 Oct;161(4):1199-206.

21.

Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration.

Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, Kelly WK, Kattan MW.

J Clin Oncol. 2002 Oct 1;20(19):3972-82.

PMID:
12351594
22.

Quantifying the amount of variation in survival explained by prostate-specific antigen.

Verbel DA, Heller G, Kelly WK, Scher HI.

Clin Cancer Res. 2002 Aug;8(8):2576-9.

23.

Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer.

Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac H, Siedlecki K, Verbel D, Schwartz L, Larson SM, Scher HI.

Urology. 2002 Jun;59(6):913-8.

PMID:
12031380
24.

17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.

Solit DB, Zheng FF, Drobnjak M, M√ľnster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N.

Clin Cancer Res. 2002 May;8(5):986-93.

25.

HER-2 profiling and targeting in prostate carcinoma.

Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, Osman I, Scher HI.

Cancer. 2002 Feb 15;94(4):980-6.

26.

Two-stage designs for gene-disease association studies.

Satagopan JM, Verbel DA, Venkatraman ES, Offit KE, Begg CB.

Biometrics. 2002 Mar;58(1):163-70.

PMID:
11890312
27.

HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer.

Osman I, Scher HI, Drobnjak M, Verbel D, Morris M, Agus D, Ross JS, Cordon-Cardo C.

Clin Cancer Res. 2001 Sep;7(9):2643-7.

28.

Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery.

Kushner BH, Wolden S, LaQuaglia MP, Kramer K, Verbel D, Heller G, Cheung NK.

J Clin Oncol. 2001 Jun 1;19(11):2821-8.

PMID:
11387353

Supplemental Content

Loading ...
Support Center